440 related articles for article (PubMed ID: 17761193)
1. Upregulation of the ligand-RAGE pathway via the angiotensin II type I receptor is essential in the pathogenesis of diabetic atherosclerosis.
Ihara Y; Egashira K; Nakano K; Ohtani K; Kubo M; Koga J; Iwai M; Horiuchi M; Gang Z; Yamagishi S; Sunagawa K
J Mol Cell Cardiol; 2007 Oct; 43(4):455-64. PubMed ID: 17761193
[TBL] [Abstract][Full Text] [Related]
2. RAGE axis: Animal models and novel insights into the vascular complications of diabetes.
Naka Y; Bucciarelli LG; Wendt T; Lee LK; Rong LL; Ramasamy R; Yan SF; Schmidt AM
Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1342-9. PubMed ID: 15155381
[TBL] [Abstract][Full Text] [Related]
3. Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway.
Nagai N; Izumi-Nagai K; Oike Y; Koto T; Satofuka S; Ozawa Y; Yamashiro K; Inoue M; Tsubota K; Umezawa K; Ishida S
Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4342-50. PubMed ID: 17724226
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin II upregulates RAGE expression on podocytes: role of AT2 receptors.
Rüster C; Bondeva T; Franke S; Tanaka N; Yamamoto H; Wolf G
Am J Nephrol; 2009; 29(6):538-50. PubMed ID: 19129693
[TBL] [Abstract][Full Text] [Related]
5. The angiotensin receptor blocker, telmisartan, reduces and stabilizes atherosclerosis in ApoE and AT1aR double deficient mice.
Fukuda D; Enomoto S; Hirata Y; Nagai R; Sata M
Biomed Pharmacother; 2010 Dec; 64(10):712-7. PubMed ID: 20970951
[TBL] [Abstract][Full Text] [Related]
6. Activation of the ROCK1 branch of the transforming growth factor-beta pathway contributes to RAGE-dependent acceleration of atherosclerosis in diabetic ApoE-null mice.
Bu DX; Rai V; Shen X; Rosario R; Lu Y; D'Agati V; Yan SF; Friedman RA; Nuglozeh E; Schmidt AM
Circ Res; 2010 Apr; 106(6):1040-51. PubMed ID: 20133903
[TBL] [Abstract][Full Text] [Related]
7. Deletion of angiotensin II type 2 receptor exaggerated atherosclerosis in apolipoprotein E-null mice.
Iwai M; Chen R; Li Z; Shiuchi T; Suzuki J; Ide A; Tsuda M; Okumura M; Min LJ; Mogi M; Horiuchi M
Circulation; 2005 Sep; 112(11):1636-43. PubMed ID: 16145000
[TBL] [Abstract][Full Text] [Related]
8. Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression.
Yamagishi S; Matsui T; Nakamura K; Inoue H; Takeuchi M; Ueda S; Fukami K; Okuda S; Imaizumi T
Microvasc Res; 2008 Jan; 75(1):130-4. PubMed ID: 17560613
[TBL] [Abstract][Full Text] [Related]
9. Pigment-epithelium-derived factor suppresses expression of receptor for advanced glycation end products in the eye of diabetic rats.
Yamagishi S; Matsui T; Nakamura K; Yoshida T; Takeuchi M; Inoue H; Yoshida Y; Imaizumi T
Ophthalmic Res; 2007; 39(2):92-7. PubMed ID: 17284935
[TBL] [Abstract][Full Text] [Related]
10. Receptor for advanced glycation end products is involved in impaired angiogenic response in diabetes.
Shoji T; Koyama H; Morioka T; Tanaka S; Kizu A; Motoyama K; Mori K; Fukumoto S; Shioi A; Shimogaito N; Takeuchi M; Yamamoto Y; Yonekura H; Yamamoto H; Nishizawa Y
Diabetes; 2006 Aug; 55(8):2245-55. PubMed ID: 16873687
[TBL] [Abstract][Full Text] [Related]
11. Deposition of advanced glycation end products (AGE) and expression of the receptor for AGE in cardiovascular tissue of the diabetic rat.
Sun M; Yokoyama M; Ishiwata T; Asano G
Int J Exp Pathol; 1998 Aug; 79(4):207-22. PubMed ID: 9797717
[TBL] [Abstract][Full Text] [Related]
12. Gene expression of receptor for advanced glycosylation end products and its modulation by aminoguanidine in diabetic kidney tissue.
Huang Y; Lin S; Zhou J
Chin Med J (Engl); 1998 Aug; 111(8):698-704. PubMed ID: 11245022
[TBL] [Abstract][Full Text] [Related]
13. RAGE mediates oxidized LDL-induced pro-inflammatory effects and atherosclerosis in non-diabetic LDL receptor-deficient mice.
Sun L; Ishida T; Yasuda T; Kojima Y; Honjo T; Yamamoto Y; Yamamoto H; Ishibashi S; Hirata K; Hayashi Y
Cardiovasc Res; 2009 May; 82(2):371-81. PubMed ID: 19176597
[TBL] [Abstract][Full Text] [Related]
14. Advanced glycation end-product Nε-carboxymethyl-Lysine accelerates progression of atherosclerotic calcification in diabetes.
Wang Z; Jiang Y; Liu N; Ren L; Zhu Y; An Y; Chen D
Atherosclerosis; 2012 Apr; 221(2):387-96. PubMed ID: 22305260
[TBL] [Abstract][Full Text] [Related]
15. Deletion of bone marrow-derived receptor for advanced glycation end products inhibits atherosclerotic plaque progression.
Morris-Rosenfeld S; Blessing E; Preusch MR; Albrecht C; Bierhaus A; Andrassy M; Nawroth PP; Rosenfeld ME; Katus HA; Bea F
Eur J Clin Invest; 2011 Nov; 41(11):1164-71. PubMed ID: 21418204
[TBL] [Abstract][Full Text] [Related]
16. The long-term effect of angiotensin II type 1a receptor deficiency on hypercholesterolemia-induced atherosclerosis.
Eto H; Miyata M; Shirasawa T; Akasaki Y; Hamada N; Nagaki A; Orihara K; Biro S; Tei C
Hypertens Res; 2008 Aug; 31(8):1631-42. PubMed ID: 18971539
[TBL] [Abstract][Full Text] [Related]
17. Critical role of bone marrow angiotensin II type 1 receptor in the pathogenesis of atherosclerosis in apolipoprotein E deficient mice.
Fukuda D; Sata M; Ishizaka N; Nagai R
Arterioscler Thromb Vasc Biol; 2008 Jan; 28(1):90-6. PubMed ID: 17962627
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model.
Wang K; Zhou Z; Zhang M; Fan L; Forudi F; Zhou X; Qu W; Lincoff AM; Schmidt AM; Topol EJ; Penn MS
J Pharmacol Exp Ther; 2006 Apr; 317(1):37-43. PubMed ID: 16368901
[TBL] [Abstract][Full Text] [Related]
19. Quinapril treatment abolishes diabetes-associated atherosclerosis in RAGE/apolipoprotein E double knockout mice.
Watson AM; Li J; Samijono D; Bierhaus A; Thomas MC; Jandeleit-Dahm KA; Cooper ME
Atherosclerosis; 2014 Aug; 235(2):444-8. PubMed ID: 24945577
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products.
Kaji Y; Usui T; Ishida S; Yamashiro K; Moore TC; Moore J; Yamamoto Y; Yamamoto H; Adamis AP
Invest Ophthalmol Vis Sci; 2007 Feb; 48(2):858-65. PubMed ID: 17251488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
